tradingkey.logo

Johnson & Johnson Announces Approval Of Subcutaneous Rybrevant®▼ By European Commission

ReutersFeb 23, 2026 5:27 PM

- Johnson & Johnson JNJ.N:

  • SUBCUTANEOUS RYBREVANT®▼ (AMIVANTAMAB) APPROVED BY EUROPEAN COMMISSION FOR EVERY-THREE-WEEK AND EVERY-FOUR-WEEK DOSING FOR PATIENTS WITH ADVANCED EGFR-MUTATED NON-SMALL CELL LUNG CANCER

  • J&J: SC AMIVANTAMAB IS NOW AUTHORISED FOR USE ACROSS ALL PREVIOUSLY APPROVED INTRAVENOUS (IV) AMIVANTAMAB INDICATIONS-WEBSITE

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI